XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Cash flows from operating activities:              
Net loss $ (129,172,466) $ (33,135,404) $ (29,579,076) $ (29,288,867) $ (162,307,870) $ (58,867,943)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,608,060 1,863,225  
Amortization of intangible assets 137,000   267,000   273,540 533,126  
Change in fair value of derivative liability         110,976,977 0  
Stock-based compensation         7,663,988 6,787,991  
Non-cash interest expense         3,013,942 2,851,031  
Amortization of premiums on investments         0 1,962  
Loss on short-term investments         576,001 (93,273)  
Settlement of receivable with shares of common stock from affiliated entity (PLS)         (1,713,770) 0  
Gain on deconsolidation of Geneos (4,121,075)   0   (4,121,075) 0  
(Gain) loss on equity investment in affiliated entities 3,883,176   173,212   (9,298,443) 923,315  
Share of net loss in Geneos 901,757   0   901,757 0  
Net unrealized loss on available-for-sale equity securities         691,458 0  
Non-cash lease expense         517,865 412,533  
Tax benefit from other unrealized gains on short-term investments         0 (335,228)  
Unrealized transaction loss on foreign-currency denominated debt         (474,071) 0  
Changes in operating assets and liabilities:              
Accounts receivable         (2,813,086) 3,186,131  
Accounts receivable from affiliated entities         865,832 (258,353)  
Prepaid expenses and other current assets         (3,084,082) (902,772)  
Prepaid expenses and other current assets from affiliated entities         (1,330,601) 20,059  
Other assets         116,242 (183,091)  
Accounts payable and accrued expenses         (732,774) (9,187,074)  
Accrued clinical trial expenses         2,882,486 (1,033,367)  
Accounts payable and accrued expenses due to affiliated entities         4,634 (324,224)  
Deferred revenue         (92,426) (137,046)  
Deferred revenue from affiliated entities         62,500 62,500  
Operating lease right-of-use assets and liabilities, net         (1,022,951) (786,079)  
Grant funding liability         4,265,023 (1,695,191)  
Grant funding liability from affiliated entities         (63,050) 817,125  
Other liabilities         29,686 (34,688)  
Net cash used in operating activities         (52,604,208) (56,379,331)  
Cash flows from investing activities:              
Purchases of investments         (138,698,249) (73,698,391)  
Proceeds from sale or maturity of investments         47,455,067 46,688,689  
Purchases of capital assets         (176,534) (739,808)  
Decrease in cash resulting from the deconsolidation of Geneos         2,774,851 0  
Net cash used in investing activities         (94,194,567) (27,749,510)  
Cash flows from financing activities:              
Proceeds from issuance of convertible senior notes         0 75,658,953  
Proceeds from issuance of common stock, net of issuance costs         329,960,855 2,296,316  
Proceeds from stock option exercises         9,599,514 92,272  
Taxes paid related to net share settlement of equity awards         (2,076,567) (892,928)  
Acquisition of non-controlling interest         2,379,969 3,016,538  
Proceeds from Geneos issuance of note payable         171,620 0  
Net cash provided by financing activities         340,035,391 80,171,151  
Effect of exchange rate changes on cash and cash equivalents         0 0  
Increase (Decrease) in cash and cash equivalents         193,236,616 (3,957,690)  
Cash and cash equivalents, beginning of period   $ 22,196,097   $ 23,693,633 22,196,097 23,693,633 $ 23,693,633
Cash and cash equivalents, end of period $ 215,432,713   $ 19,735,943   215,432,713 19,735,943 $ 22,196,097
Supplemental disclosures:              
Amounts accrued for purchases of property and equipment         1,620 0  
Interest paid         2,636,454 0  
Right-of-use assets obtained in exchange for lease obligations         $ 0 $ 14,634,769